AbbVie Stock News

AbbVie and Gilead Sciences haven't been recording excellent financial results lately. But both drugmakers have solid lineups and pipelines that should allow them to recover.

AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript)

In the latest trading session, AbbVie (ABBV) closed at $179.86, marking a -0.59% move from the previous day.

US stocks climbed higher in February with the DJIA adding 0.4% and the S&P closing in on the 5,000-point mark.

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In investing, where uncertainty often reigns high, dividend kings are the beacons of income stability and growth. Among them, three companies hold enduring leads.

At first glance, another gangbusters jobs report seems to imply that dividend stocks are irrelevant. It's all about growth, baby!

Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.

AbbVie's full-year results for 2023 might have been weak, but its price is still up by 15% YTD. The disconnect is explained by the revenue dip because of patent expiration for its blockbuster drug Hum

Last year emerged as a time of unexpected resilience and expansion for the stock market driven by the strength of unstoppable mega-cap stocks. Notably, the S&P 500 wrapped up last year with a solid 24

Both of these healthcare giants are leaders in their industries and faithful dividend payers. AbbVie is dealing with short-term challenges, but the strength of its underlying business remains intact.

AbbVie is a leading pharmaceutical company with a diverse portfolio of products and strong revenue growth. The company has a solid track record of increasing dividends and offers an attractive current

AbbVie is a pharmaceutical company with a strong history of growth and income generation for investors. The company has a robust pipeline of products in various stages of development, particularly in

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

AbbVie (ABBV) closed the most recent trading day at $180.57, moving -0.27% from the previous trading session.